BACE1 and Alzheimer disease: Thus, cholinesterases (ChEs, e.g., AChE, BChE), β-site amyloid precursor protein cleaving enzyme 1 (BACE1), and glycogen synthase kinase-3β (GSK-3β) are considered as important targets for anti-AD drugs [9].